The Redcliffe Labs acquisition of Pune-based Megavision Diagnostics Centre in a deal valued at approximately ₹40 crore was announced on 11 August 2026, as publicly reported on 2026-08-11. The transaction sees Noida-headquartered Redcliffe Labs move decisively into western India, adding advanced radiology and imaging capabilities to its established pathology platform. The deal is the latest in a series of inorganic moves by Redcliffe as it pursues an integrated diagnostics strategy across the country.
Quick Highlights
- Acquirer: Redcliffe Labs
- Target: Megavision Diagnostics Centre
- Deal Value: ₹40 crore (approx. $4.14 million)
- Founders (Redcliffe Labs): Aditya Kandoi and Dheeraj Jain
- Headquarters (Redcliffe Labs): Noida, Uttar Pradesh, India
- Target Location: Pimpri and Nigdi, Pune, Maharashtra, India
- Announcement Date: 11 August 2026
Deal Breakdown
Deal Rationale
Redcliffe Labs built its business primarily around pathology and home diagnostics, but radiology is a capital-intensive segment requiring significant infrastructure investment. As publicly reported, the company’s strategy is to build imaging capabilities rapidly through acquisitions rather than setting up centres from scratch. Megavision, founded in 1996, operates two MRI-equipped diagnostic centres in Pune’s Pimpri and Nigdi areas offering MRI, CT scans, mammography, sonography, ECG, and EEG services — making it a ready-made infrastructure asset. Megavision generates annual revenues of approximately ₹20 crore and carries over two decades of clinical credibility in the Pimpri-Chinchwad market. This acquisition also marks Redcliffe’s first strategic investment in western India, as publicly reported, enabling it to expand beyond its stronghold in northern India.
Deal Structure
The transaction is valued at approximately ₹40 crore. As publicly reported, the deal is expected to close within the same month of its announcement. Redcliffe Labs will retain Megavision’s entire existing workforce following the completion of the transaction, ensuring continuity of patient care. Dr. Kedar Prabhakar Bhate, who has led Megavision, will continue to lead the combined entity — operating as Megavision Redcliffe Labs — and will work with Redcliffe’s Clinical Board to strengthen radiology services across Pune and surrounding areas. Both businesses will operate under the Redcliffe Medicentre Imaging & Labs brand, as publicly reported.
Expansion Plans
Redcliffe Labs is targeting revenue of approximately ₹700 crore for FY27, implying nearly 50% year-on-year growth driven by both organic expansion and further acquisitions, as publicly reported. The company plans to expand integrated diagnostics — combining pathology and advanced imaging — across Pune and nearby regions following the Megavision integration. Dr. Bhate will work alongside Redcliffe’s Clinical Board specifically to grow radiology services in western India. Redcliffe’s acquisition-led strategy also recently added Kota-based Prime Sonography and Diagnostic Center and Ajmer-based Sarvodaya Diagnostics in Rajasthan, signalling continued geographic expansion across India.
Significance
This deal signals a meaningful shift in Redcliffe Labs’ business model — from a pathology-first, home-collection platform to a fully integrated diagnostics provider capable of delivering both lab and imaging services under one roof. For a company that has grown revenues at a compound annual rate of approximately 40% against an industry average of 10–11%, as publicly reported, adding MRI-equipped centres in Pune accelerates its march toward higher-value radiology revenue without the capital drag of greenfield construction. More broadly, the acquisition reflects a consolidation wave sweeping India’s diagnostics sector in 2026, with established chains and genomics players alike using inorganic deals to deepen geographic reach and layer specialised capabilities onto existing networks. For Redcliffe, securing a foothold in western India through a trusted, decades-old brand like Megavision is a strategically efficient route to building the scale and service breadth needed to compete with listed diagnostics incumbents.
These details have been verified against multiple publicly available reports as of 2026-08-11.
Stay updated with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
